Latest advances in CAR-T therapy for CLL and Richter’s transformation

2 Views

07/14/23

Adam Kittai, MD, Ohio State University, Columbus, OH, provides insight into ongoing studies investigating CAR-T therapy for patients with chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT), including lisocabtagene maraleucel (liso-cel) alone or in combination with ibrutinib, axicabtagene ciloleucel (axi-cel), and ROR1-directed CAR-T therapy in CLL, and brexucabtagene autoleucel (brexu-cel), and liso-cel and zanubrutinib in RT. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.